Table of Content

Executive Summary

Chapter 1 – Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharmaceuticals and biotechnology
1.4. Royalties versus revenue share
1.5. Overview of the report

Chapter 2 – An overview of pharmaceutical and biotechnology royalty rates
2.1. Trends in royalty rates 2010 - 2023
2.2. How do revenue shares figure?
2.3. A review of recent literature
2.4. Royalty rates in the future

Chapter 3 – The royalty clause in pharmaceutical and biotechnology deals
3.1. Partnering agreement structure
3.2. Structure of a typical royalty clause
3.3. Example royalty clauses
3.3.1. Case study 1
3.3.2. Case study 2
3.3.3. Case study 3
3.3.4. Case study 4

Chapter 4 – Companies actively disclosing royalty rates
4.1. Most active companies in disclosing royalty rates

Chapter 5 – Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight

Deal Directory
Deal Directory – Royalty rates in deals – by company A-Z
Deal Directory – Royalty rates in deals - by therapy area
Deal Directory – Royalty rates in deals - by stage of development at signing
Deal Directory – Royalty rates in deals - by technology type

Royalty rate references
Example royalty rate deal contract document
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures
Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2023
Figure 2: Components of the partnering deal structure
Figure 3: Components of the partnering royalty clause
Figure 4: Most active companies disclosing royalty rate 2010 - 2023
Figure 5: Licensing agreement for rhAAT – rEVO Biologics, LFB Biotechnologies